SBRT2015

Teaching goals

Understand comparative effectiveness research (CER), and how it led to SBRT becoming a guideline-recommended standard of care. Know why aging populations and comorbidity are both likely to lead to SBRT being used in operable patients with Stage I NSCLC. Understand why advances in systemic therapy will lead to increasing clinical demands for SBRT in metastatic disease. Be aware of the focus on ‘ value ’ in healthcare, and the role of patient reported outcomes, in determining reimbursements.